TY  - JOUR
AU  - Paz-Ares, Luis
AU  - Spigel, David R
AU  - Chen, Yuanbin
AU  - Jove, Maria
AU  - Juan-Vidal, Oscar
AU  - Rich, Patricia
AU  - Hayes, Theresa
AU  - Calderón, Vanesa Gutiérrez
AU  - Caro, Reyes Bernabe
AU  - Navarro, Alejandro
AU  - Dowlati, Afshin
AU  - Zhang, Bin
AU  - Moore, Yan
AU  - Yao, Xiaopan
AU  - Kokhreidze, Jaba
AU  - Ponce, Santiago
AU  - Bunn, Paul A
PY  - 2022
DO  - 10.1002/cncr.34123
UR  - http://hdl.handle.net/10668/21507
T2  - Cancer
AB  - RESILIENT (NCT03088813) is a phase 2/3 study assessing the safety, tolerability, and efficacy of liposomal irinotecan monotherapy in patients with small cell lung cancer and disease progression on/after first-line platinum-based therapy. Here, we...
LA  - en
KW  - chemotherapy
KW  - liposomal irinotecan
KW  - platinum-resistant disease
KW  - small cell lung cancer
KW  - subsequent therapy
KW  - Aged
KW  - Diarrhea
KW  - Disease Progression
KW  - Humans
KW  - Irinotecan
KW  - Liposomes
KW  - Lung Neoplasms
KW  - Middle Aged
KW  - Neutropenia
KW  - Small Cell Lung Carcinoma
TI  - RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
TY  - research article
VL  - 128
ER  -